Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RDPTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Radiopharm Theranostics Limited (RDPTF) SEC filings provide U.S. investors with access to information originally released to the Australian Securities Exchange. As a foreign private issuer, the company files annual reports on Form 20-F and furnishes current reports on Form 6-K under Rules 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
In its Form 6-K submissions, Radiopharm Theranostics Limited includes an explanatory note describing the public notice it published to the Australian Securities Exchange and attaches that notice as an exhibit. Examples include a filing that furnishes a "Corporate Governance Statement and Appendix 4G" and another that furnishes a "Pivalate (Brain Mets) key opinion leader webinar" announcement. These filings clarify that the reports, including exhibits, are not deemed "filed" for purposes of the Exchange Act and are not incorporated by reference into Securities Act filings unless specifically stated.
On this page, you can review Radiopharm Theranostics’ Form 6-K and Form 20-F submissions as they appear in the SEC’s EDGAR system. The platform offers real-time updates when new filings are furnished, along with AI-powered summaries that explain the key points in plain language. This can help readers understand the substance of governance documents like the corporate governance statement and Appendix 4G, as well as the focus of materials such as the Pivalate (Brain Mets) key opinion leader webinar.
In addition to current reports, investors can use this page to locate the company’s annual Form 20-F, which provides a broader overview of its status as a foreign private issuer. Where applicable, insider transaction reports on Form 4 and other relevant filings can also be accessed, with AI tools highlighting important sections and clarifying technical terminology.
Radiopharm Theranostics Ltd director Noel Donnelly has reported his initial derivative holdings in the company. He holds options to buy 5,333,333 Ordinary Shares at an exercise price of $0.0600 per share, expiring on September 30, 2029, granted on December 16, 2024.
According to the grant terms, 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027, provided he remains a director on those dates.
Radiopharm Theranostics Ltd director Ian Lawrence Turner has filed an initial Form 3 detailing his equity position in RADX. The filing shows direct ownership of 6,985,292 Ordinary Shares and indirect ownership of 3,000,000 Ordinary Shares held through the Turner Discretionary Trust, where he is the sole beneficiary.
Mr. Turner also holds multiple option awards over Ordinary Shares with exercise prices ranging from 0.0250 to 0.2000 per share and expirations between 2026 and 2030. Footnotes explain that several grants vest in tranches between July 2026 and July 2028, in some cases only if he remains a director or achieves specified milestones.
Radiopharm Theranostics Ltd Managing Director and CEO Riccardo Canevari has filed a Form 3 reporting his initial ownership position. The filing shows direct ownership of 22,679,986 Ordinary Shares, along with multiple option awards over additional Ordinary Shares at exercise prices ranging from $0.025 to $0.60 per share and expirations between 2026 and 2030.
Footnotes state that significant blocks of options granted in 2023, 2024 and 2025 will vest in stages on July 1 of 2026, 2027 and 2028, provided Mr. Canevari remains a Director on those dates.
Radiopharm Theranostics Ltd director Hester Denise Larkin filed an initial ownership report showing direct holdings in ordinary shares and stock options. She holds 644,247 ordinary shares directly. She also holds options to buy ordinary shares, including 275,000 shares at $0.06 per share expiring on August 24, 2026, and larger grants such as 5,333,333 shares at $0.06 per share expiring on September 30, 2029. A December 16, 2024 grant provides 2,666,667 options vesting September 30, 2026 and 2,666,666 vesting September 30, 2027 if she remains a director, alongside additional options at $0.60 per share expiring December 1, 2026.
Radiopharm Theranostics Limited reported that it has dosed the first patient in its first-in-human Phase 1 clinical trial of RAD 402 for advanced prostate cancer. This early-stage study will assess safety, tolerability, whole-body distribution, and initial signs of clinical activity.
RAD 402 is a monoclonal antibody targeting KLK3, radiolabelled with Terbium 161, aiming to selectively attack KLK3-expressing prostate tumors while limiting damage to healthy tissue. Preclinical mouse xenograft data showed strong tumor targeting, minimal bone and marrow uptake, and hepatic clearance, and the company expects to share data from the first two dose levels in the second half of 2026.
Radiopharm Theranostics Limited reported second interim data from its U.S. Phase 2b imaging trial of RAD101 in brain metastases. In 20 treated patients, 90% (18/20) achieved the primary endpoint of concordance between PET imaging with RAD101 and MRI, with significant and selective tumor uptake observed in brain metastases.
The first five patients with six‑month follow-up and/or biopsy data showed an encouraging trend for sensitivity and specificity, key measures of diagnostic accuracy. The company expects final data from the full 30‑patient study by June to help guide a potential pivotal trial. RAD101 has FDA Fast Track Designation for distinguishing recurrent brain metastases from treatment effects.
Radiopharm Theranostics Limited reports that it has dosed the first patient in its first‑in‑human Phase 1/2a clinical trial of 177Lu‑BetaBart (RV-01), a radiopharmaceutical developed through Radiopharm Ventures, the joint venture with The University of Texas MD Anderson Cancer Center.
The Phase 1/2a study is a dose escalation and expansion trial designed to evaluate safety, biodistribution, pharmacokinetics and radiation dosimetry of 177Lu‑BetaBart, as well as preliminary anti‑tumor activity, and to determine a recommended dose for later studies. The trial aims to enroll 61 participants with advanced solid tumors, including castrate resistant prostate, colorectal, lung, head and neck, ovarian, cervical, endometrial, triple negative breast and esophageal squamous cell cancers.
Preclinical animal studies of RV-01 have shown tumor shrinkage and prolonged survival, and 177Lu‑BetaBart targets the 4Ig isoform of B7‑H3, an immune checkpoint molecule overexpressed across several tumor types. Management describes this as the first radiotherapeutic agent from the joint venture to enter the clinic, highlighting progress in the company’s radiotherapeutic pipeline.
Radiopharm Theranostics reported half-year fiscal 2026 results and clinical updates, highlighting progress across multiple radiopharmaceutical programs and a strengthened cash position.
Interim Phase 2b data for RAD 101 in brain metastases showed that 92% of evaluable participants met the primary MRI concordance endpoint. RAD 101 holds FDA Fast Track Designation and its U.S. trial aims to complete enrollment in the first quarter of 2026. Phase 1 programs RAD 202 (HER2) and RAD 204 (PD-L1) continued, with RAD 202 cleared by the Data Safety and Monitoring Committee to escalate to a 75mCi dose.
The company also advanced preclinical assets RV-01 (B7H3) and RAD 402 (KLK3), and is planning a Phase 2 imaging trial for RAD 301 in loco-regional pancreatic cancer, which already has FDA Orphan Drug Designation. Quarterly cash flow data show operating outflows of A$13.38 million, license fee payments of A$4.55 million, equity proceeds of A$35.26 million and period-end cash and cash equivalents of A$34.52 million, which the company states provide runway into 2027.
Radiopharm Theranostics Limited (RDPTF) reported a challenging year ending June 30, 2025, with a total comprehensive loss of A$37.88 million and negative operating cash flows of approximately A$36.65 million. The group recorded accumulated losses of A$145.73 million and significant research and development investment, including R&D expenses of A$27.52 million (line item) and intangible assets on the balance sheet of A$49.09 million.
The company generated other income including an R&D tax incentive (A$9.37 million recognised) and raised cash from financing activities (A$45.43 million reported in one table). Key governance and management details are disclosed, including CEO Riccardo Canevari and a Board with named directors and option/share holdings. The filing also discloses material contingent consideration balances, significant finance expenses and assumptions used in impairment and contingent consideration models.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing furnishes as an exhibit a Public Notice dated September 17, 2025 titled “Corporate Governance Statement and Appendix 4G.”
The attached materials relate to the company’s corporate governance disclosures and associated compliance appendix. The Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated by reference into other Securities Act filings unless specifically referenced.